PRESS RELEASES

July 29th, 2009

Boston Imaging Core Lab and Chondrometrics form Partnership to Extend Their Services and Advance Osteoarthritis Research


Chondrometrics GmbH, Ainring, Germany, and Boston Imaging Core Lab (BICL), LLC, Boston, MA, announced today the formation of a partnership between the two companies in order to broaden and advance their capabilities for offering imaging biomarker analysis to osteoarthritis researchers in academia and pharmaceutical industry.

Chondrometrics GmbH is a leading provider of software-based quantitative medical image analysis, with a focus on articular cartilage and other joint structure in osteoarthritis. BICL is a leading provider of semi-quantitative radiological reading services, which are based on advanced radiological scoring systems, including all relevant joint tissues affected by osteoarthritis.

"We are excited about this partnership and look forward to extending our already strong research collaboration into a closer strategic co-operation between the two companies," said BICL President Dr. Guermazi in Boston.

"This will allow us to offer the full spectrum of osteoarthritis imaging biomarkers, both quantitative and semi-quantitative, which recent research has been proven to provide complimentary and synergistic rather than competing or overlapping information in clinical trials," said Chondrometrics CEO Dr. Eckstein.

The partnership teams Dr. Ali Guermazi, also Section Chief of Musculoskeletal Radiology at the Department of Radiology, Boston University School of Medicine, with Dr. Felix Eckstein, also Director of the Institute of Anatomy and Musculoskeletal Research at Paracelsus Medical University in Salzburg Austria.Both are internationally recognized experts in the field of osteoarthritis imaging and pioneers of quantitative and semi-quantitative imaging biomarkers using advanced radiological imaging techniques.

"Together, we will be able to offer a strong and comprehensive portfolio of imaging biomarkers to our partners and clients, unmet by other providers in the field. Also, we will use our synergies and experience to further develop and validate advanced imaging biomarkers. This will allow our partners and clients to detect disease risk factors in clinical trials with higher efficiency and should accelerate the development of drugs, particularly for osteoarthritis and other joint diseases," said both experts during a meeting in Boston on July 28th, 2009.


July 5th, 2009

Montreal Based ArthroVision Inc. Accepts Court Decision and Abandons German Part of Osteoarthritis Research Related Patent EP 1230561AINRING, GermanyCHONDROMETRICS-GMBH

Chondrometrics GmbH announced today that ArthroVision Inc., a wholly-owned subsidiary of Horizon Sciences & Technologies Inc., Montreal, has accepted the decision of the District Court of Munich, Germany from March 19th 2009 that Chondrometrics GmbH does not make use of the claims of ArthroVision's patent EP 1 230 561 and therefore does not infringe on the German part of the patent. ArthroVision has withdrawn its appeal for the first instance judgment to be taken to the 2nd level of jurisdiction and thus accepts the decision as being final.

Montreal based ArthroVision Inc. has also abandoned the German part of the Osteoarthritis research related European patent EP 1 230 561 (Title: Evaluating Disease Progression using Magnetic Resonance Imaging) and waived all claims against Chondrometrics GmbH based on this patent for the past, in view of an invalidity complaint filed by Chondrometrics GmbH in the German Federal Patent Court of Munich.


April 3rd, 2009

German Court Finds ArthroVision's Patent Not Infringed by Chondrometrics